Nixol introduces a new natural supplement in the United Kingdom to support metabolism, curb cravings, and promote healthy ...

Abvance Therapeutics, a biotechnology company developing next generation glucagon analogs and therapies to prevent hypoglycemia and improve glucose management, today announced the presentation of new ...

Foundation announced yesterday its role as a founding member of the RLT Angels Association together with leading organizations in the field of radiotheranostics namely the European Association of ...

The Kingdom concludes BIO 2025 with a clear message: Saudi Arabia is open for collaboration, primed for innovation, and committed to lasting partnerships.

The Merger Agreement has been unanimously recommended by a Special Committee of the independent directors of Enzon and a Special Committee of the independent directors of Viskase and, acting upon such ...

Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a ...

ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced ...

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug ...

About amycretin Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an efficacious and convenient treatment for adults with ...

The Ensign Group, Inc. (Nasdaq: ENSG or “Ensign”), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational ...

The Inducement Grant has a ten-year term and an exercise price per share of $9.97, which is equal to the closing price of Zenas’ common stock on the Grant Date. The Inducement Grant will vest over a ...

The net proceeds of the offering shall be used for working capital and general corporate purposes. Based on its current operating assumptions, Cyclacel expects this financing, together with Cyclacel’s ...